BioPharm International, January 2007 - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

BioPharm International, January 2007
Features
Supply Chain Management: Delivering on the Promise: Building an Effective Supply Chain
By Todd Applebaum
The supply chain can be used as a tool for managing not only product supply risks, but overall business risks as well.
Salary Survey: Is Your Paycheck as Robust as Your Proteins?
By Marilyn Kochman
The biotechnology industry is thriving, and hopefully you are too. BioPharm International's first salary and employee satisfaction survey presents a wealth of data that will allow you to compare many aspects of your job with those of your peers. The survey reports on demographics, education, work experience, salary and benefits, and attitudes toward current employment.
Downstream Processing: A Revalidation Study of Viral Clearance in the Purification of Monoclonal Antibody CB.Hep-1
By María del Rosario Alemán , Enrique Noa , Andrés Tamayo , Marta Dubed , Sigifredo Padilla , Giselle Alvarez , Déborah Geada , Lamay Dorta , Leonor Navea , Tatiana González , Biunayki Reyes , Eutimio Gustavo Fernández , Rodolfo Valdés
The HSV-1 and HVP-2 titers were determined by the inoculation of test solutions into Vero cell cultures and calculated using the Reed M?ench method.
Columns and Departments
China Today: Defining the Chinese Biopharmaceutical Market
By Eliza Yibing Zhou , Eric S. Langer
China is home to more than 400 biogeneric manufacturers, which develop generic biopharmaceuticals for the domestic population.
From the Editor: Aggregate Knowledge
By Laura Bush
Given the complexity involved in the causes, mechanisms, and kinetics of protein aggregation, industry leaders and academics should continue to share knowledge and experience in this area.
Outstourcing Insights Lonza Commits to Life Sciences Sector
By Jim Miller
The number of projects in Lonza's internal biomanufacturing pipeline grew by 40% to over 75 projects.
IP Briefs: Demystifying the Patent Reform Act and its Impact on Company IP Strategy
By David A. Gay , William Gaede
The Act will establish third party rights to challenge the validity of a patent through postgrant opposition proceedings.
Street Talk: Biopharm Exchange-Traded Funds: Their Time has Come
By Brian O'Connell
On a recent plane ride from Phoenix to Philly, I was leafing through a copy of the San Francisco Business Journal. I was taken aback by a story on the emerging trend of biopharm exchange-traded funds (ETFs), and how much of an impact they're having on Wall Street and on investors.
Final Word: Regulatory Evolution
By Benjamin Locwin
How much do regulatory agencies know about nanotechnology or microfluidics? Yesterday, the answer was probably, "not much." Tomorrow, it may be "a lot." The reason is that new technologies push the agencies to expand their expertise.
Regulatory Beat: Multiple Issues Challenge Biotech Industry in 2007
By Jill Wechsler
FDA is encouraging broader use of pharmacogenomic data by offering manufacturers early informal advice.

ADVERTISEMENT

ADVERTISEMENT

Click here